Delivering best-in-class multispecifics for medicines that matter
Engineering the optimal multispecific for every therapeutic challenge, with IgG-like developability
Developing best-in-class multispecifics
Numab’s Fc engineered precision multispecifics with extended half-life
Numab’s Fc engineering technologies enable the design of long-acting multispecific antibodies with tailored effector function and extended serum half-life, supporting less frequent dosing.
Different therapeutic challenges require different molecular architectures. Numab’s integrated platform spans a broad multispecific antibody design space, enabling the rational selection and optimization of multispecific formats according to target biology, mechanism of action, and target product profile. The platform supports the routine generation of multispecific antibodies with up to six specificities while maintaining IgG-like stability, manufacturability, and CMC properties. Fc engineering enables further optimization of half-life and effector function, while resulting molecules can be developed for intravenous or subcutaneous administration.
Numab’s Multispecific Antibody-based Therapeutics by Cognate Heterodimerization (MATCHTM) with a compact design
Numab’s proprietary MATCH™ technology enables the design of compact multispecific antibodies optimized for efficient tissue penetration where molecular size is a critical therapeutic consideration.
MATCH™ expands Numab’s antibody design space beyond conventional IgG-like architectures, enabling compact multispecific molecules with properties tailored to tissue-access requirements, target biology, and mechanism of action. Integrated with Numab’s broader multispecific platform and complementary Fc engineering technologies, MATCH™ supports the rational selection and optimization of molecular architectures according to the target product profile. This flexibility enables the development of differentiated multispecific therapeutics where efficient tissue penetration and access to challenging anatomical compartments are important for therapeutic activity.
Engineering stable, humanized antibody building blocks
Engraftment of rabbit CDR onto a stable human framework incorporating λ-Cap™ and λ-Stealth™ technologies
Numab’s λ-Cap™ and λ-Stealth™ technologies provide stable, humanized scFv building blocks with the biophysical and functional properties required for multispecific antibody development.
Based on a fully human consensus scaffold, λ-Cap™ enhances scFv stability while preserving the affinity, specificity, and biological activity of the parental antibody. λ-Stealth™ is designed to prevent binding by pre-existing anti-drug antibodies, an important factor in controlling immunogenicity. Together with Numab’s advanced humanization strategy, these technologies preserve target-binding properties while enhancing stability, manufacturability, and overall developability, providing optimized building blocks for diverse multispecific antibody architectures.
Discovering ultra-high-affinity antibody leads
Millions of antibody candidates. One purpose: discovering best-in-class therapeutics.
Numab’s antibody discovery combines the diversity of the rabbit immune repertoire with advanced screening technologies to identify differentiated, ultra-high-affinity antibody building blocks for multispecific therapeutics.
The broad epitope diversity of the rabbit immune repertoire enables the discovery of antibodies with picomolar-range affinity, high target specificity, and potent biological activity, including against challenging or difficult-to-target antigens. By integrating high-throughput screening, advanced discovery technologies, and antibody engineering expertise, Numab rapidly identifies candidates with the binding and functional properties required for multispecific antibody development.